1. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Issue 10358 (1st October 2022) Authors: Livingstone, Elisabeth; Zimmer, Lisa; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas K; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kiecker, Felix; Dippel, Edgar; Roesch, Alexander; Ziemer, Mirj... Journal: Lancet Issue: Volume 400:Issue 10358(2022) Page Start: 1117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10236 (16th May 2020) Authors: Zimmer, Lisa; Livingstone, Elisabeth; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kieker, Felix; Dippel, Edgar; Rösch, Alexander; Simon, Jan-Chris... Journal: Lancet Issue: Volume 395:Issue 10236(2020) Page Start: 1558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗